Literature DB >> 15233732

DNA vaccines against human immunodeficiency virus type 1.

Marie J Estcourt1, Andrew J McMichael, Tomás Hanke.   

Abstract

Development of a vaccine against human immunodeficiency virus type 1 (HIV-1) is the main hope for controlling the acquired immunodeficiency syndrome pandemic. An ideal HIV vaccine should induce neutralizing antibodies, CD4+ helper T cells, and CD8+ cytotoxic T cells. While the induction of broadly neutralizing antibodies remains a highly challenging goal, there are a number of technologies capable of inducing potent cell-mediated responses in animal models, which are now starting to be tested in humans. Naked DNA immunization is one of them. This review focuses on the stimulation of HIV-specific T cells and discusses in the context of the current 'state-of-art' of DNA vaccines, the areas where this technology might assist either alone or as a part of more complex vaccine formulations in the HIV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15233732     DOI: 10.1111/j.0105-2896.2004.00151.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  10 in total

1.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice.

Authors:  Nazli Jafarpour; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Fatemeh Kohram; Haniyeh Aghababa; Nima Khoramabadi; Mehdi Mahdavi
Journal:  Mol Biol Rep       Date:  2014-05-20       Impact factor: 2.316

3.  Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Simon Beddows; Norbert Schülke; Marc Kirschner; Kelly Barnes; Michael Franti; Elizabeth Michael; Thomas Ketas; Rogier W Sanders; Paul J Maddon; William C Olson; John P Moore
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Immune hierarchy among HIV-1 CD8+ T cell epitopes delivered by dendritic cells depends on MHC-I binding irrespective of mode of loading and immunization in HLA-A*0201 mice.

Authors:  Henrik N Kloverpris; Ingrid Karlsson; Mette Thorn; Søren Buus; Anders Fomsgaard
Journal:  APMIS       Date:  2009-11       Impact factor: 3.205

5.  Long-term storage of DNA-free RNA for use in vaccine studies.

Authors:  Kathryn L Jones; Debbie Drane; Eric J Gowans
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

Review 6.  HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies.

Authors:  Nyasha Chin'ombe; Vurayai Ruhanya
Journal:  Pan Afr Med J       Date:  2015-04-20

7.  Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.

Authors:  Jun Huang; Rui Ma; Chang-you Wu
Journal:  Vaccine       Date:  2006-04-04       Impact factor: 3.641

8.  Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.

Authors:  Mark Matijevic; Mary Lynne Hedley; Robert G Urban; Roman M Chicz; Christa Lajoie; Thomas M Luby
Journal:  Cell Immunol       Date:  2011-04-23       Impact factor: 4.868

9.  Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides.

Authors:  Snehlata Tripathi; Binay Chaubey; Sabyasachi Ganguly; Dylan Harris; Ralph A Casale; Virendra N Pandey
Journal:  Nucleic Acids Res       Date:  2005-08-02       Impact factor: 16.971

10.  Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.

Authors:  Emma-Jo Hayton; Annie Rose; Umar Ibrahimsa; Mariarosaria Del Sorbo; Stefania Capone; Alison Crook; Antony P Black; Lucy Dorrell; Tomáš Hanke
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.